TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14597105
Drug: Prior to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to treatment
Study: 10595630
Drug: Clopidogrel 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 50 mg/od
Study: 10595630
Drug: Ticlopidine 250
Normalized name: ticlopidine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 250 mg/bid
Study: 9226734
Drug: Amisulpride 50
Normalized name: amisulpride 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 50 mg
Study: 10890311
Drug: Amisulpride 200
Normalized name: amisulpride 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 200 mg
Study: 11123382
Drug: Ethanol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.8 g/kg)
Study: 8911882
Drug: Amisulpride 50
Normalized name: amisulpride 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 50 mg and 200 mg
Study: 6108756
Drug: Oral beta-blockers
Normalized name: beta carotene Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beta-blockers (atenolol and propranolol) combined with topical epinephrine
Study: 6108756
Drug: Timolol (local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (local beta-blocker)
Study: 25348661
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir (ETV) monotherapy (0.5 mg/day)
Study: 9447901
Drug: Ciprofloxacin for
Normalized name: Ciprofloxacin for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin for seven days, 500 mg b.i.d. (Group 1, 25 patients)
Study: 9447901
Drug: Ciprofloxacin for
Normalized name: Ciprofloxacin for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin for ten days, 750 mg b.i.d. (Group 2, 25 patients)
Study: 2881038
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (20 mg/kg intramuscularly daily for the first 3 days of life)
Study: 25196897
Drug: Recombinant FVIII
Normalized name: HUMAN COAGULATION FACTOR VIII (FVIII, ANTIHEMOPHILIC FACTOR, AHF, PROCOAGULANT COMPONENT) WITH DELETED B-DOMAIN (746-1639)-SEQUENCE: SINGLE-CHAIN RECOMBINANT FVIII COMPOSED OF DOMAINS A1-A1-A2-A2 (1-740), THE B-DOMAIN N-AND C-TERMINAL FRAGMENTS (741-745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant FVIII Fc fusion protein (rFVIIIFc) weekly prophylaxis
Study: 31113841
Drug: Onalespib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onalespib (120 mg/m2 on day 1 and day 2 weekly for 3 of 4 weeks) + Abiraterone Acetate + Prednisone/Prednisolone
Study: 23588127
Drug: Empiric antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric antibiotic treatment
Study: 27759808
Drug: Maintenance modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance modified electroconvulsive therapy (MECT) combined with risperidone
Study: 25662558
Drug: Methocarbamol/paracetamol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methocarbamol/paracetamol combination treatment
Study: 22087616
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (20-minute massage by parents at home before bedtime every night for 5 weeks, in addition to standard asthma treatment)
Study: 22087616
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard asthma treatment alone for 5 weeks)
Study: 14673051
Drug: Itraconazole cyclodextrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole cyclodextrine solution
Study: 10629018
Drug: Itraconazole capsules
Normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole capsules
Study: 10817039
Drug: Iopromide (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopromide (n = 16; median volume 102 ml; 95% confidence interval 90‐108 ml)
Study: 10817039
Drug: Ioxaglate (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ioxaglate (n = 15; median volume 105 ml; 95% confidence interval 95‐114 ml)
Study: 1918842
Drug: Sucralfate, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate, 2 g b.i.d.
Study: 2093019
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg b.i.d.
Study: 3932570
Drug: Proluton, 50‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proluton, 50‐mg daily injections given on days 7‐16 following oocyte recovery
Study: 31838377
Drug: Sodium selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium selenite (SS) 400 μg elemental Se, taken orally daily for 8 weeks
Study: 31113455
Drug: LBEC0101 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBEC0101 (50 mg) administered subcutaneously once per week for 48 weeks
Study: 12100776
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice daily
Study: 11087881
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg daily
Study: 1873773
Drug: Bolus doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus doxorubicin (60 mg/m2 every 3 to 4 weeks)
Study: 1873773
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion doxorubicin (60 mg/m2 every 3 to 4 weeks)
Study: 1873773
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion doxorubicin
Study: 7631286
Drug: Beta-blocking agents
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocking agents
Study: 28752937
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behaviour therapy (ICBT)
Study: 12925474
Drug: Diclofenac 1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 1.1 mg kg(‐1) alone
Study: 1737157
Drug: Omeprazole 80
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 80 mg intravenously immediately, then three doses of 40 mg intravenously at eight hourly intervals, then 40 mg orally at 12 hourly intervals for four days
Study: 20472045
Drug: Low-frequency ultrasound
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency ultrasound (US) applied during 5 min with a 36 kHz probe, pulsed mode (2s on/5s off), intensity of 2.72 W/cm², with betamethasone 17-valerate cream, 2-hour occlusion.
Study: 20472045
Drug: Topical steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids with 1-hour occlusion.
Study: 18630537
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with massage of sole and oral administration of Alprazolam
Study: 3595698
Drug: Nitrazepam 5
Normalized name: nitrazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam 5 mg
Study: 7049583
Drug: Chlormezanone 400
Normalized name: chlormezanone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormezanone 400 mg
Study: 8315953
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy (control)
Study: 25694153
Drug: Posterior scleral
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior scleral reinforcement (PSR) combined with patching therapy
Study: 19145002
Drug: Low-sodium PD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium PD fluid with [Na+] = 102 mmol/l (group B)
Study: 16887727
Drug: Artemether-lumefantrine treatment
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine treatment
Study: 15253711
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion in ESRD patients
Study: 15253711
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion in healthy controls
Study: 9052418
Drug: Clodronate (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (1600 mg daily) with antioestrogens
Study: 9052418
Drug: Antioestrogens only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioestrogens only (20 mg tamoxifen or 60 mg toremifene daily)
Study: 7689752
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) infusion during OLT
Study: 27020594
Drug: Propofol (3-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (3-5 mg/kg i.v.)
Study: 27020594
Drug: Sevoflurane (8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane (8% inhaled)
Study: 21346020
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for insomnia
Study: 15651516
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml fentanyl
Study: 8956390
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ketamine
Study: 11705075
Drug: Pentaglobin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaglobin (5 ml/kg/day for 3 days)
Study: 2655491
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections (alginate diluent with some containing 5 micrograms of histamine)
Study: 31489422
Drug: HCQ+modified Xiaoyao
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCQ+modified Xiaoyao pill
Study: 20605091
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (ascorbic acid 120 mg, vitamin E 30 mg, β-carotene 6 mg, selenium 100 μg, zinc 20 mg)
Study: 9403646
Drug: Ibuprofen (10.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (10.3 ± 1.9 mg/kg)
Study: 9403646
Drug: Paracetamol (9.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (9.8 ± 1.9 mg/kg)
Study: 20675882
Drug: Other drugs
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drugs and newly developed drugs
Study: 23066663
Drug: Oral PUVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PUVA
Study: 18219455
Drug: Shenyi Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenyi Capsule
Study: 18219455
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Shenyi Capsule plus chemotherapy)
Study: 29945738
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg/day)
Study: 17339122
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) administration
Study: 6640551
Drug: 5‐FU at
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU at a dose of 400 mg/m2/day iv X 5 plus TZT at a dose of 175 mg/m2/day iv X 3 (FT)
Study: 6640551
Drug: 5‐FU at
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU at a dose of 400 mg/m2/day plus ICRF‐159 at a dose of 600 mg/m2/day orally X 3 (FI)
Study: 31034525
Drug: Balanced gelatine/electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced gelatine/electrolyte solution
Study: 31034525
Drug: Non-balanced gelatine/electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-balanced gelatine/electrolyte solution
Study: 9616507
Drug: Turbuhaler (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbuhaler (50 micrograms dose -1)
Study: 9616507
Drug: pMDI (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: pMDI (100 micrograms dose -1) with spacer (Volumatic)
Study: 23650968
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC)
Study: 3182592
Drug: Ephedrine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (24 mg)
Study: 31190492
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of auricular point pressing and EA
Study: 18273622
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections of ranibizumab (3 injections)
Study: 16828478
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OCs) for 21 days
Study: 16828478
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH-a) for 14 days
Study: 9082867
Drug: Single-dose spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose spinal anaesthesia (n = 150)
Study: 3090127
Drug: Balloon reservoir
Normalized name: RESERVOIR,CADD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon reservoir volume of 3 l
Study: 3090127
Drug: Balloon reservoir
Normalized name: RESERVOIR,CADD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon reservoir volume of 18 l
Study: 3090127
Drug: Balloon reservoir
Normalized name: RESERVOIR,CADD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon reservoir volume of 24 l
Study: 26684635
Drug: Methylsulfonylmethane (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylsulfonylmethane (5 g) and Boswellic acids (7.2 mg)
Study: 18515507
Drug: Antibiotics (cefotetan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (cefotetan or cefoxitin)
Study: 15937676
Drug: Video group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video group (one-time oral instruction by a physiotherapist and issued a video for home exercise)
Study: 15937676
Drug: Training group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training group (exercise therapy; physiotherapist-guided; two times a week for 8 weeks)
Study: 17876370
Drug: Topical nitroglycerin
Normalized name: nitroglycerin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerin
Study: 10816228
Drug: Control ointment
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control ointment (polysporin)
Study: 8871001
Drug: Synchronous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synchronous chemotherapy with the 3M regimen (mitoxantrone, methotrexate and Mitomycin‐C) during radiotherapy (CRT)
Study: 8871001
Drug: Synchronous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synchronous chemotherapy with the 3M regimen (CRT)
Study: 1728624
Drug: Predetermined meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predetermined meal three times daily (including cottage cheese, apple sauce, vanilla ice cream, and other selected foods)
Study: 27552545
Drug: GH (0.67
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH (0.67 mg/m2 · d)
Study: 16222518
Drug: Insulin-induced antilipolysis
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-induced antilipolysis and lipogenesis
Study: 10468684
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg, amoxycillin 1 g, clarithromycin 500 mg (RAC)
Study: 10468684
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg, metronidazole 400 mg, tetracycline 1 g (RMT)
Study: 10468684
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg plus clarithromycin 500 mg for 2 weeks (RC-2)
Study: 8522636
Drug: Moexipril (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril (7.5 mg and 15 mg once daily)
Study: 8522636
Drug: Verapamil (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (180 mg and 240 mg once daily)
Study: 1964898
Drug: Canned baked
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canned baked beans (6 cans of 440 g per week)
Study: 7457945
Drug: Fentanyl citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl citrate administered intramuscularly at 0.006 mg/kg
Study: 7457945
Drug: Morphine chlorhydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine chlorhydrate administered at 0.150 mg/kg
Study: 27655223
Drug: WBRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBRT plus 50 mg veliparib BID (n=103)
Study: 27655223
Drug: WBRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBRT plus 200 mg veliparib BID (n=102)
Study: 25872665
Drug: Jingui external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jingui external lotion
Study: 16453952
Drug: Secondary intention
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary intention closure (gel foam applied for hemostasis)
Study: 15602019
Drug: Palifermin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palifermin (60 microg/kg/day for 3 days before and after conditioning therapy)
Study: 15602019
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous for 3 days before and after conditioning therapy)
Study: 7923644
Drug: Heparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5000 U bolus and infusion of 1000 U/h for patients < 80 kg or 1300 U/h for patients >= 80 kg)
Study: 15631970
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy website (MoodGYM) - public registrants
Study: 8784087
Drug: Troglitazone 200
Normalized name: troglitazone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 200 mg
Study: 9667800
Drug: Troglitazone 200-600
Normalized name: troglitazone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 200-600 mg
Study: 11297595
Drug: Troglitazone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (all doses)
Study: 31886854
Drug: Preoperative screening
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative screening for Staphylococcus aureus nasal carriers and selective 5-day decolonization using mupirocin ointment (experimental group).
Study: 24577485
Drug: High-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose edoxaban
Study: 24577485
Drug: Low-dose edoxaban
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose edoxaban
Study: 18188164
Drug: Dual blockade
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual blockade treatment with candesartan (16 mg o.d.) and lisinopril (20 mg o.d.)
Study: 18188164
Drug: High-dose lisinopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose lisinopril (40 mg o.d.)
Study: 12059892
Drug: Mivacurium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium (0.1 mg/kg bolus followed by continuous infusion)
Study: 9522671
Drug: Aspirin 2
Normalized name: aspirin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 2 x 500 mg (acetylsalicylic acid)
Study: 7510063
Drug: Nurse home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse home visitation during pregnancy (treatment 3)
Study: 7510063
Drug: Nurse home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse home visitation during pregnancy and the first 2 years of the child's life (treatment 4)
Study: 7510063
Drug: Sensory and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensory and developmental screening at ages 1 and 2 years (treatment 1)
Study: 7510063
Drug: Screening plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening plus free transportation for prenatal and well‐child care (treatment 2)
Study: 796937
Drug: Ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 100 mg/day
Study: 26510086
Drug: Fluvastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin + Standard of Care (SOC) therapy (PEG-IFN/Ribavirin) for 48 weeks
Study: 26510086
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care (SOC) therapy (PEG-IFN/Ribavirin) for 48 weeks
Study: 21606531
Drug: H5N1 A/Indonesia/05/2005
Approvals — FDA: no, EMA: no, PMDA: no
Description: H5N1 A/Indonesia/05/2005 vaccine (3.75 μg hemagglutinin antigen, AS03(A) adjuvanted)
Study: 8136093
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR (240 to 480 mg/day)
Study: 30030128
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) ghrelin
Study: 18028434
Drug: G‐CSF +
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF + EPO
Study: 12918185
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg morphine sulfate p.o. approximately one hour before surgery
Study: 11583481
Drug: Rofecoxib 12.5
Normalized name: rofecoxib 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 12.5 mg once daily
Study: 23993259
Drug: Ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 800 mg 3 times daily
Study: 8211024
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 to 40 mg daily)
Study: 20889387
Drug: Lidocaine patch
Normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine patch
Study: 29395412
Drug: Depressomassage (additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depressomassage (additional to standard physical therapy)
Study: 24812900
Drug: Lingtong Capsule
Normalized name: BUTYLENE GLYCOL 1.6 g in 8 g CUTANEOUS TAPE [LingLongJiuHuo Linglong Moxibustion]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lingtong Capsule (LC)
Study: 23192920
Drug: 1 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 × 10(5) autologous CD34+ cells/kg (low-dose)
Study: 23192920
Drug: 1 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 × 10(6) autologous CD34+ cells/kg (high-dose)